Enveric Biosciences, Inc. (ENVB)
1.46
+0.04
(+2.82%)
USD |
NASDAQ |
Oct 28, 15:24
Enveric Biosciences Free Cash Flow : -8.561M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.561M |
| March 31, 2026 | -8.007M |
| December 31, 2025 | -8.142M |
| September 30, 2025 | -7.668M |
| June 30, 2025 | -6.520M |
| March 31, 2025 | -7.519M |
| December 31, 2024 | -7.726M |
| September 30, 2024 | -8.166M |
| June 30, 2024 | -9.979M |
| March 31, 2024 | -11.56M |
| December 31, 2023 | -14.10M |
| September 30, 2023 | -15.82M |
| June 30, 2023 | -17.65M |
| March 31, 2023 | -17.82M |
| December 31, 2022 | -17.73M |
| September 30, 2022 | -18.52M |
| June 30, 2022 | -16.16M |
| March 31, 2022 | -13.54M |
| December 31, 2021 | -12.32M |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| September 30, 2020 | -2.155M |
| June 30, 2020 | -2.281M |
| March 31, 2020 | -2.435M |
| Date | Value |
|---|---|
| December 31, 2019 | -2.537M |
| September 30, 2019 | -2.977M |
| June 30, 2019 | -3.760M |
| March 31, 2019 | -3.090M |
| December 31, 2018 | -2.566M |
| September 30, 2018 | -2.512M |
| June 30, 2018 | -1.330M |
| March 31, 2018 | -2.357M |
| December 31, 2017 | -2.746M |
| September 30, 2017 | -1.514M |
| June 30, 2017 | -4.239M |
| March 31, 2017 | -1.976M |
| December 31, 2016 | -2.704M |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | -0.0166M |
| December 31, 2014 | -0.0432M |
| September 30, 2014 | -0.0396M |
| June 30, 2014 | -0.0461M |
| March 31, 2014 | -0.0372M |
| December 31, 2013 | -0.0216M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| LENZ Therapeutics, Inc. | -114.42M |
| Impact BioMedical, Inc. | -0.508M |
| ANI Pharmaceuticals, Inc. | 167.52M |
| Corcept Therapeutics, Inc. | 106.92M |
| Veru, Inc. | -26.04M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -2.444M |
| Cash from Financing (Quarterly) | 5.845M |
| Free Cash Flow Per Share (Quarterly) | -0.6131 |
| Free Cash Flow to Equity (Quarterly) | -2.444M |
| Free Cash Flow to Firm (Quarterly) | -2.444M |
| Free Cash Flow Yield | -341.3% |